Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only


| Attribute | ||
|---|---|---|
Research Summary | AICAR tricks your body into thinking it just did a massive workout, even if it was just sitting still. It turns on your fat-burning mode and makes muscles act like they have been exercising for hours. | Imagine your cells have a tiny engine that burns fat, but sometimes a heavy brake gets stuck on it. 5-Amino-1MQ removes that brake so your cells can burn energy faster and shrink fat cells without you having to eat less. |
Studied For | AMPK / metabolic-stress researchInsulin-resistance modelsEndurance researchExercise mimeticFat oxidation via AMPKGlucose uptake enhancementCardiac protection / ischemiaObesity modelsMetabolic syndrome researchWADA prohibited performance substance researchMitochondrial biogenesisType 2 diabetes modelsCancer metabolism researchAMPK pathway signalingAnti-inflammatory via AMPKendurance enhancementfat burningmetabolic regulatorischemic protectionmuscle metabolism | Obesity / metabolic syndromeFat-loss / energy-expenditure researchNAD+ metabolism enhancementNNMT inhibitionAdipogenesis inhibitionAdipocyte differentiation blockingLean mass preservationInsulin sensitivity improvementLipid metabolismDiet-induced obesity modelsWeight management without appetite suppressionSAM (S-adenosyl methionine) pool preservationEpigenetic metabolic regulationMitochondrial efficiencyExercise performancefat burningmetabolism boosterweight lossmuscle wasting preventioncellular energyanti-agingNAD+ salvage pathway |
Research Areas | MetabolicPerformance & MuscleMitochondrial Function | MetabolicWeight Management & Fat LossMitochondrial FunctionPerformance & Muscle |
Best Stacked With | mots-cnad-plusl-carnitinebac-water | nad-plusmots-cl-carnitinebac-water |
Overview | ||
Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
Compound Class | Purine nucleoside analog; cell-permeable AMPK activator (converted intracellularly to ZMP) | Small-molecule NNMT inhibitor (quinolinium salt); not a peptide |
Molecular Target | AMP-activated protein kinase (AMPK) activation via ZMP (AMP mimetic); PGC-1alpha upregulation; GLUT4 translocation; mitochondrial biogenesis | Nicotinamide N-methyltransferase (NNMT) inhibition; preserves SAM and NAD+ pools; reduces adipogenesis; enhances energy expenditure |
Aliases / AKA | AcadesineAICA-riboside5-aminoimidazole-4-carboxamide ribonucleotideAICAR nucleosideZMP precursorAcadesine AICAR | 5-Amino-1-methylquinolinium5A1MQ5-amino-1-methylquinolinium saltNNMT inhibitor 5-amino-1mqNicotinamide N-methyltransferase inhibitor5-amino 1MQ |
Parent Compound | ZMP precursor | 1-methylnicotinamide mimic |
Molecular Weight | 258.23 Da | 159.21 Da |
Amino Acid Sequence | small molecule nucleoside | small molecule (quinolinium) |
CAS Number | 2627-69-2 | 685079-15-6 (iodide salt) |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 2,818 Extensive | 152 Moderate |
Clinical Trials | Not Listed | Not Listed |
Regulatory Status | Investigational / research chemical; WADA-prohibited at all times (metabolic modulator, AMPK activator). | Not approved; research chemical. |
Evidence & Regulatory | ||
Half-Life | ~2 hours | ~4 hours |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | Mostly in vitro and animal: increased glucose uptake, fat oxidation, and running endurance. Acadesine reached human cardiac-surgery trials but was never approved. No established human metabolic or performance efficacy. | Diet-induced-obese mice showed reduced body weight and fat mass without changed food intake. There are no completed published human trials; all claims are animal or in vitro. Preliminary. |
Side Effects Noted | Transient hyperuricemia and headache in cardiac trials; broad AMPK activation can be context-dependently tumor-promoting; long-term human safety unknown. | No adverse effects in short rodent studies; essentially no human safety data; chronic effects on the methylation pool are uncharacterized. |
Warnings | Investigational with no safe non-clinical dose. WADA-prohibited at all times (AMPK activator). Research use only. | Strictly investigational with no human approval and no defined human dose. CAS and salt form should be verified against a supplier certificate of analysis. |
Pharmacology | ||
Form | solid | solid (iodide salt) |
Diluent | water or DMSO for stock | water or DMSO for stock |
Storage Temp | cold, desiccated, dark | cold, desiccated, dark |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | Use solutions fresh. | Prepare fresh. |
Reconstituted Shelf Life | 14 Days Refrigerated | 28 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Single BPC-157 versus the combined BPC-157 and TB-500 blend in recovery research.
Ipamorelin alone versus the CJC-1295 and ipamorelin blend on the growth-hormone axis.
A synthetic ACTH-fragment nootropic versus a neurotrophic peptide preparation in cognitive research.
Two sleep-research compounds with distinct mechanisms.
A copper tripeptide versus an acetyl hexapeptide in cosmetic and skin research.
A senolytic peptide versus a telomerase-pathway peptide in longevity research.
Two metabolic research compounds targeting the AMPK and NNMT pathways.
A GHRH analog versus an HGH fragment in fat-metabolism research.
Two AMPK-associated mitochondrial and metabolic research compounds.
Two peptides studied for tissue protection and repair.
Two peptides studied for immune and inflammatory modulation.
Two peptide bioregulators studied in longevity and neuro research.
A glucagon/GLP-1 dual agonist versus a GIP/GLP-1 dual agonist in metabolic research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.